It has been more than a year-and-a-half since the FDA released its publication “An update to the Resiliency Roadmap for FDA Inspections.” Are you among the many companies wanting to stay current and who can benefit from some assistance in creating an executable year-to-year plan to maintain both long and short-term inspection proactivity? If so, insight can be gained via a recent FDA presentation that outlines simple directions for calendar year 2023 per its published roadmap.
Our Contract Pharma article, “FDA 2023 Inspection Roadmap: Is ‘Readiness’ in Your Annual Objectives?” provides oversight and perspective on the latest information on the subject. In this valuable read, Patrick Day, M.S., Principal Consultant, Lachman Consultants, explores a wide range of issues that relate to the FDA and its transparency in projecting its intentions and inspection plans. It also provides access to a variety of sources that can aid in an organization’s activities on the journey to achieving “readiness.”
